Our 5 research axes

Servier focuses its R&D on 5 therapeutic areas. Within each of them,
the Group has chosen to specialize in a limited number of diseases
where medical needs remain major.

    Cardiovascular diseases

    14
    Medicines to treat heart failure
    2 nd
    Player in the Pharmaceutical
    Industry in Europe
    fighting against these diseases
    16 million
    Of patients treated
    per day worldwide

    Cardiovascular disease is the leading cause of death worldwide. Due to its considerable and growing impact on public health, cardiovascular disease is a crucial focus of our in-house research and development, and has been for decades. In this field, we are currently No. 2 in Europe. We now have 14 therapeutics available, primarily in high blood pressure, heart failure, and venous diseases.

    At present, we are pursuing the clinical development of molecular entities in heart failure, stroke, and venous disease complications. In addition, we have partnered with Amgen on the final stage of clinical development of omecamtiv mecarbil, an innovative and promising chronic heart failure treatment. Innovative research programs for the treatment of heart failure in all its forms are underway.

    In addition, Wehealth by Servier our eHealth department looks forward to providing patients with innovative eHealth solutions for better care, such as Cardioskin, an intelligent piece of clothing which detects heart rhythm disorders.